Current guidelines of the global initiative for asthma (GINA) recommend the addition of biologics in step 5 of the stepwise asthma treatment approach. This review gives an overview on the effects and the clinical role of antibodies targeting immunoglobulin E, IgE (Omalizumab), Interleukin-5, IL-5 (Mepolizumab, Reslizumab) or the IL-5 receptor (Benralizumab). In addition, potential future treatment options of refractory asthma with antibodies (for instance Dupilumab) are discussed.
CITATION STYLE
Lommatzsch, M. (2016). Therapie des refraktären Asthmas mit Antikörpern. Deutsche Medizinische Wochenschrift, 141(11), 790–793. https://doi.org/10.1055/s-0042-107044
Mendeley helps you to discover research relevant for your work.